Form 4: Nanophase Technologies Corp: Officer Kevin Cureton Exercises Options

Sentiment:

SEC Form 4 Filing


Kevin Cureton, Chief Operating Officer of Nanophase Technologies Corp, exercised options to acquire 50,000 shares of common stock at $0.44 per share on March 21, 2024.

Summary

  • On March 21, 2024, Kevin Cureton, the Chief Operating Officer of Nanophase Technologies Corp, exercised options to purchase 50,000 shares of common stock at a price of $0.44 per share.
  • Following this transaction, Cureton directly owns 175,821 shares of Nanophase Technologies Corp.
  • Cureton also holds options to purchase additional shares at various exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of an officer exercising stock options. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the trading behavior of company executives and directors, which can be informative for investors.

Stakeholder Impact

  • The exercise of options by a company officer can be viewed by shareholders as a sign of confidence in the company's future prospects, or it could be seen as diluting the value of existing shares.

Key Dates

DateDescription
02/18/2016Date of options grant with expiration 02/18/2025, exercise price $0.44
02/23/2017Date of options grant with expiration 02/23/2026, exercise price $0.42
02/21/2018Date of options grant with expiration 02/21/2027, exercise price $0.68
05/23/2019Date of options grant with expiration 05/23/2028, exercise price $0.82
05/22/2020Date of options grant with expiration 05/22/2029, exercise price $0.51
06/18/2021Date of options grant with expiration 06/18/2027, exercise price $0.45
12/28/2022Date of options grant with expiration 12/28/2028, exercise price $4.17
12/20/2023Date of options grant with expiration 12/20/2029, exercise price $1.165
03/21/2024Kevin Cureton exercised options for 50,000 shares at $0.44.
03/25/2024Date of signature for the Form 4 filing.
12/27/2024Date of options grant with expiration 12/27/2030, exercise price $0.61

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.